Delegates will hear from a wide range of speakers and panellists including, Andrew Dillon, Chief Executive of NICE, Miles Ailing, Director of Innovation at NHS England, Dr Jeremy Haigh, European Chief Operating Officer, Research & Development at Amgen Ltd, Dr Doug Brown, Director of Research and Development, at the Alzheimer’s Society, Dr Penny Dash, Director, at McKinsey and Stephen Whitehead ABPI Chief Executive. Speakers and panel members will also include representatives from industry and patient groups.
The ABPI will also be launching a new publication at the event - The future innovation landscape- which will provide an overview on the changes to drug development, requiring greater links between commercial and R&D environments. The report will also explore how the NHS could adapt to this new environment to ensure the UK remains at the forefront of R&D.
Commenting on the conference ABPI Chief Executive Stephen Whitehead said:
“Our conference will be held at a time when we are seeing a shift in the medicines development paradigm, the commercial world along with the research and development environments will inevitably come together as we move towards more pre-competitive collaboration, a more pragmatic approach to clinical development of medicines and regulators/ HTA bodies working closer together on the evaluation and appraisal of medicines.
This conference is a must for anyone operating in the UK commercial environment and suitable for any member of the industry from senior managers, market access, communications, commercial and account management”.
To register or find out more about the conference visit our annual conference registration site.
There will be complimentary (day) delegate passes available for media via the registration website.
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811 Email: firstname.lastname@example.org
Notes to editors
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.